First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study

Alexandre Hideo-Kajita, Hector M. Garcia-Garcia*, Michael Haude, Michael Joner, Jacques Koolen, Hüseyin Ince, Alexandre Abizaid, Ralph Toelg, Pedro A. Lemos, Clemens von Birgelen, Evald Høj Christiansen, William Wijns, Franz Josef Neumann, Christoph Kaiser, Eric Eeckhout, Lim Soo Teik, Javier Escaned, Viana Azizi, Kayode O. Kuku, Yuichi OzakiKazuhiro Dan, Ron Waksman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Introduction and objective: The edge vascular response (EVR)remains unknown in second generation drug-eluting Resorbable Magnesium Scaffold (RMS), such as Magmaris. The aim of the study was to evaluate tissue modifications in the RMS edges over time, assessed by different invasive imaging modalities. Methods: The patients treated with the device were assessed by optical coherence tomography (OCT), grayscale intravascular ultrasound (IVUS), and virtual histology IVUS at baseline and 12 months. The EVR study performed a segment- and frame-level analysis of the 5 mm segments proximal and distal of the actual RMS. Results: The segment-level grayscale IVUS (n = 10), virtual histology IVUS (n = 10), and OCT (n = 18)analysis did not show any significant changes after 12 months, except for a fibrous plaque area (FPA)reduction of 0.5mm 2 (p = 0.017)in the proximal segment compared to baseline. In the frame-level analysis, IVUS evaluation revealed a vessel area decreased 2.80 ± 1.43 mm 2 (p = 0.012)and 2.49 ± 1.53 mm 2 (p = 0.022)in 2 proximal frames. This was accompanied by plaque area reduction of 0.88 ± 0.70 mm 2 (p = 0.048)and a FPA decreased by 0.63 ± 0.48 mm 2 (p = 0.004)in one proximal frame. In 1 distal frame, there was a dense calcium area reduction of 0.10 ± 0.12 mm 2 (p = 0.045), FPA and fibrous fatty plaque increased 0.54 ± 0.53 mm 2 (p = 0.023)and 0.17 ± 0.16 mm 2 (p = 0.016), respectively. By OCT, there was a lumen area decrease of 0.76 ± 1.51 mm 2 (p = 0.045)in a distal frame. Conclusion: At 12 months, Magmaris EVR assessment does not show overall significant changes, except for a fibrous plaque area reduction in the proximal segment. This could be translated as a benign healing process at the edges of the RMS. The edge vascular response (EVR)remains unknown in second generation drug-eluting absorbable metal scaffolds (RMS), such as Magmaris. Patients treated with the device were assessed by multi invasive imaging modalities [i.e. optical coherence tomography (OCT), grayscale intravascular ultrasound (IVUS), and virtual histology IVUS]evaluating the tissue changes over time in the segment- and frame-level analysis of the 5 mm segments proximal and distal of the actual RMS. As a result, after 12 months, Magmaris EVR assessment does not show overall significant changes, except for a fibrous plaque area reduction in the proximal segment, translating a benign healing process at the edges of the RMS.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalCardiovascular Revascularization Medicine
Volume20
Issue number5
DOIs
Publication statusPublished - 1 May 2019
Externally publishedYes

Keywords

  • Edge vascular response
  • Grayscale intravascular ultrasound
  • Magmaris
  • Optical coherence tomography
  • Virtual histology

Fingerprint

Dive into the research topics of 'First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study'. Together they form a unique fingerprint.

Cite this